Tradestie Institutional Equity Comparison Engine

BGM vs ONCY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ONCY Overall Edge

ONCY Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Oncolytics Biotech, Inc. Common Shares (ONCY) driven by superior Valuation, Growth & Margin while BGM counters with relative strength in Momentum & Technical. Fundamentally, BGM trades at N/M Forward P/E with -23.4% operating margin (+69.8% YoY revenue) versus ONCY at 45.5x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, BGM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ONCY sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner ONCY
BGM N/M vs ONCY 45.5x Fwd P/E
Growth & Margin Winner ONCY
Op Margin -23.4% vs 0.0% ยท YoY +69.8% vs +0.0%
Momentum & Technical Winner BGM
1Y -17.5% vs -66.3% ยท 52W Pos 74% vs 2%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
BGM NASDAQ
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
1M Return -21.57%
1Y Return -17.53%
Forward P/E N/M
Unified AI Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
ONCY NASDAQ
Oncolytics Biotech, Inc. Common Shares
Pharmaceutical Preparations
$0.35
-10.37% 1D
Market Cap $53.2M
1M Return -30.01%
1Y Return -66.34%
Forward P/E 45.5x
Unified AI Score
44.5 / 100 HOLD
Tech 50.0 Fund 59.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BGM -17.53% ONCY -66.34% Spread: +56.67 pp (BGM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BGM TTM Op. Margin: -23.4% ONCY TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGM vs ONCY. Trailing 12-month operating profitability (BGM -23.4% vs ONCY 0.0%) and valuation multiples (BGM N/M vs ONCY 45.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BGM (6) vs ONCY (4)
Institutional Metric BGM ONCY Criterion Row Winner
Market Capitalization Scale $108.6M $53.2M Larger Scale BGM
Trailing P/E Ratio Valuation N/M 45.5x Lower Multiple ONCY
Forward P/E Ratio Valuation N/M 45.5x Lower Multiple ONCY
Revenue Growth (YoY) Growth +69.8% +0.0% Higher Growth BGM
Operating Margin (TTM) Profitability -23.4% 0.0% Higher Margin ONCY
Net Profit Margin Profitability -44.2% 0.0% Higher Margin ONCY
Return on Equity (ROE) Capital Efficiency -7.4% -769.1% Higher ROE BGM
52-Week Range Position Momentum 74% ($0โ€“$11) 2% ($0โ€“$1) Stronger Trend BGM
Beta / 30D Volatility Risk Regime 3.69ฮฒ ยท 80% Vol 1.34ฮฒ ยท 117% Vol Lower Realized Risk BGM
Unified Institutional Score Composite Signal 59.6 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite BGM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BGM vs ONCY Buy Guide
BGM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BGM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ONCY UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ONCY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BGM nor ONCY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.